跳至主要内容
临床试验/NCT07217483
NCT07217483招募中不适用

The Feasibility of Prolacta CR for Treatment of Neonatal Hypoglycemia

Baylor Research Institute2 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2024年10月14日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
75
试验地点
2
主要终点
NICU admission

研究概览

简要总结

Prolact CR (cream) is a fat supplement that is derived from pasteurized human donor milk. It has been utilized in babies who are born premature in the neonatal intensive care unit (NICU) setting to improve growth while avoiding cow milk exposure. There is no literature on the use of cream as a treatment for low blood glucose levels in newborns who are at risk. It is known that fat in human colostrum plays a vital role in providing energy, substrate, and stimulates gluconeogenesis. Gluconeogenesis is the process that helps in the sustainment of blood glucose. Dextrose gel that is used to treat low blood glucose levels helps in raising the blood glucose, but does not help in sustainment.

The objective of this pilot study is to evaluate the utility, feasibility, and acceptability of administering cream for the treatment of newborn low blood glucose levels in a couplet care unit. Investigators hypothesized that 3 ml/kg of cream (0.2 g/kg of carbohydrate and 0.75 g/kg of fat), if given in the place of 0.5 ml/kg (0.2 g/kg of carbohydrate) would increase and stabilize the blood glucose levels. Investigators also speculated that newborns would tolerate the cream with no adverse effects, and caregivers (nurses and parents) would find its use feasible and acceptable.

Parents of newborns with risk factors for hypoglycemia [born to mothers with diabetes, small for gestational age, large for gestational age, or late prematurity (35 to 37 weeks' gestation at birth) who intended to breastfeed exclusively will be approached to consent for the study either before or after delivery of the infant. Newborns with major congenital anomalies or those admitted immediately to the NICU after birth will be excluded.

The main questions hoping to answer

  1. What percentage of newborns receiving cream for treatment of hypoglycemia will need NICU admission for IV dextrose?
  2. How many median doses of cream are needed?
  3. What percentage of infants will be discharge exclusively feeding human milk from couplet care unit?
  4. What percentage of the surveys will show parent/nursing satisfaction with the product?

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
— 至 24 Hours(Child)
性别
All
接受健康志愿者

入选标准

  • Newborns at risk for hypoglycemia (born to mothers with diabetes, small for gestational age, large for gestational age, late preterm born 35 to 37 weeks gestational age)

排除标准

  • Newborns with major congenital anomalies
  • Newborns directly admitted to the NICU form delivery room

结局指标

主要结局

NICU admission

时间窗: Birth to hospital discharge at 2 to 5 days of life

Admission to neonatal intensive care unit for intravenous dextrose for treatment of hypoglycemia

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验